Newsletter, March 2024 Issue, No. 220
Top News
“Press Conference by the President of the JPMA” Held: Aiming to Be a Nation Where Innovation Thrives
On February 15, 2024, the “Press Conference by the Chairman of the JPMA” was held in a hybrid format—combining in-person and online participation—at Bellesalle Iidabashi Ekimae (Chiyoda Ward, Tokyo).At the start of the press conference, Hiroaki Ueno, Chairman of the JPMA, expressed his condolences for the Reiwa 6 Noto Peninsula Earthquake that occurred on January 1, 2024, and then delivered a presentation titled “Toward a Nation Where Innovation Thrives.”In his presentation, he explained the importance of appropriately evaluating innovation and outlined the pharmaceutical industry’s initiatives to strengthen Japan’s drug discovery capabilities. A lively question-and-answer session followed with 35 media representatives from 21 companies in attendance. Below is a summary of Chairman Ueno’s presentation and the Q&A session.
Topics
- "JPMA Rare Disease Day 2024 Symposium" Held
- “The 4th Japan-Vietnam Joint Symposium” Held
- “5th ICH Forum: ICH Quality Guideline Update” Held
- “Global Health Joint Conference 2023” Held; Co-hosted Symposium on “Antimicrobial Resistance (AMR) as a Global Health Challenge”
- "Regular Meeting with the European Federation of Pharmaceutical Industries and Associations (EFPIA)" Held
- "Regular Meeting with the German Association of Research-Based Pharmaceutical Companies (vfa)" Held
- “Regular Meeting with the French Pharmaceutical Industry Association (Leem)” Held
- “CMC Strategy Forum Japan 2023” Held
- “Next-Generation Adverse Event Case Evaluation Workshop” Held
Policy Research Institute Page
Comparison of New Drug Approval Status and Review Periods in Japan, the U.S., and Europe (2022)
From JPMA
Toward a Nation Where Innovation Thrives